Lactoferrin-encapsulated dichloroacetophenone (DAP) nanoparticles enhance drug delivery and anti-tumor efficacy in prostate cancer
- 7 February 2025
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 616, 217522
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- Glycolysis, the sweet appetite of the tumor microenvironmentCancer Letters, 2024
- Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killingCancer Letters, 2023
- SLC12A8 mediates TKI resistance in EGFR-mutant lung cancer via PDK1/AKT axisJournal of Cancer Research and Clinical Oncology, 2023
- Dichloroacetophenone biphenylsulfone ethers as anticancer pyruvate dehydrogenase kinase inhibitors in non-small cell lung cancer modelsChemico-Biological Interactions, 2023
- PDK1 regulates the progression of esophageal squamous cell carcinoma through metabolic reprogrammingMolecular Carcinogenesis, 2023
- Metabolic changes during prostate cancer development and progressionJournal of Cancer Research and Clinical Oncology, 2022
- PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapyApplied Materials Today, 2018
- A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumorsInvestigational New Drugs, 2015
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progressionCancer Cell, 2005